Biotech Winners: Pernix, Myriad, Repros, OraSure
In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.
In this segment, a look at some big winners during the past two days in the biotech space. Pernix saw a nearly 70% pop upward yesterday as the company settled a few housekeeping items, including hiring a new CEO, settling a pending legal matter, and securing $65 million in funding, a lifesaver compared to its cash-on-hand situation prior to this. Myriad Genetics , maker of a test for breast cancer, is up 15% after its fiscal second-quarter net income soared by 43.7%, to $50.4 million, with sales increasing $55 million, to $204.1 million. Repros Therapeutics is up 15% after positive meetings with the FDA over Androxal, its testosterone replacement drug. The company now believes it will not have to run any additional safety studies, and will be able to file for approval this year, which had investors cheering. And OraSure is up 10% after reporting strong earnings, with revenue coming in at $28.8 million, which was a 30% improvement and a solid beat.
So what's the best way for investors to play the high-risk, high-reward biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Biotech Winners: Pernix, Myriad, Repros, OraSure originally appeared on Fool.com.
David Williamson owns shares of AbbVie.. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.